Enter multiple symbols separated by commas

Novartis Drug for Osteoporosis Shows Promising Results: Study

A new study offers the millions of people who have osteoporosis the hope of taking a drug to treat it only once a year.

The New England Journal of Medicine reports that patients who got a once-a-year infusion of the Novartis drug Reclast saw a 70% reduction in the risk of spinal fractures and a 40% drop in the risk of hip fractures.

An editorial in the peer-reviewed medical journal calls the results "impressive".

Novartis hopes to win FDA approval of Reclast for post-menopausal osteoporosis by the end of this year.

It would compete in a multi-billion dollar drug segment with Roche's Boniva, Merck's Fosamax and Actonel from Sanofi-Aventis and Procter & Gamble. But many patients go off those drugs because they're cumbersome to take.

Researchers saw an abnormal heart rhythm in some Reclast patients. Novartis paid for the study.

Contact U.S. News


    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Don't Miss

  • KLM landing

    A Dutch storm violently rocked a plane as it approached for a landing, narrowly avoiding a crash on the runway.

  • Treasure hunters have found a trove of 300-year-old gold coins off the coast of Florida worth more than $1 million, NBC affiliate WESH reported.

  • Donald Trump

    Trump himself gave one of the clearest examples yet of why his candidacy is doomed to fail, and why the debate stage could be his Waterloo.

U.S. Video

  • Opening Bell, July 28, 2015

    Shark Tank's Kevin O'Leary celebrates the recent launch of the O'Shares FTSE U.S. quality dividend ETF at the NYSE and Bed, Bath, & Beyond at the Nasdaq.

  • Looking ahead to Twitter's earnings report

    CNBC's Morgan Brennan and PCMag.com Editor-in-Chief Dan Costa discuss the main points that investors should be looking out for during Twitter's earnings call after the closing bell.

  • Cramer: Hats off to China

    CNBC's Jim Cramer weighs in on China's markets, Pfizer's earnings and UPS.